News

Under terms of this new agreement, Breckenridge will submit an abbreviated new drug application (ANDA) to the FDA in 2009 for the product which is in development by

Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. The lawsuits are in response to the submission

The study evaluated the dose response, efficacy and safety of five doses of GW642444 (‘444) administered once-daily for four weeks. All doses achieved statistically significant increases in lung

Wafik El-Deiry, professor of medicine, genetics and pharmacology at the University of Pennsylvania School of Medicine and associate director for physician-scientist training in hematology/oncology at the University of

The first patient was enrolled at the University of Alabama at Birmingham. The study will be conducted at approximately 15 to 20 centers in the US, and will

Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately seven years

Baxter has acquired all rights to AV513, a compound poised for clinical research that has been shown to improve blood coagulation in preclinical models for hemophilia. Avigen has

Flamel Technologies is engaged in 17 partnered projects and is working with seven of the top-twenty pharmaceutical companies in the world, including a continuing research collaboration with Pfizer.

Since 1998, Mr Lerman has served as a litigation partner at Winston & Strawn in Chicago, where he concentrated his practice in white-collar defense, product liability and securities